Population Pharmacokinetics of Cariprazine and its Major Metabolites.

ABSTRACT:

Background and objectives

Cariprazine, a dopamine D₃-preferring D₃/D₂ receptor partial agonist, is approved for the treatment of adults with schizophrenia (1.5-6 mg/day) and manic/mixed (3-6 mg/day) episodes associated with bipolar I disorder. This population pharmacokinetic analysis describes the concentration-time profiles of cariprazine and its two major active metabolites, desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR). Additionally, the potential impact of patient characteristics, creatinine clearance, and cytochrome P450 2D6 (CYP2D6) metabolizer status on the pharmacokinetics of cariprazine and its metabolites was evaluated.

Methods

Data from three phase 1 and ten phase 2/3 studies in adult patients with schizophrenia

SUBMITTER: Periclou A 

PROVIDER: S-EPMC7811992 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature